Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.
Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.
Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.
Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.
Ginkgo Bioworks (NYSE: DNA) has partnered with Benjamin Franklin Institute of Technology (BFIT) to launch an associate degree in biotechnology manufacturing. The program aims to equip graduates for high-demand technician roles in life sciences. Funded by a $100,000 grant from the Kargman Family Foundation, the initiative supports workforce development in Massachusetts, where biotechnology jobs have surged by 67% over the past decade. The program will operate at the Nubian Square Life Science Training Center, enhancing educational access for underrepresented communities.
Ginkgo Bioworks (NYSE: DNA) announced it has detected the BA.3 sublineage of the Omicron variant in North America, sourced from passengers arriving at Newark Liberty International Airport from South Africa. This detection is part of a collaborative COVID-19 surveillance program with the CDC and XpresSpa Group (Nasdaq: XSPA), involving voluntary testing of international travelers. Over 9,000 travelers have participated, with a goal of improving public health responses to emerging variants. The findings highlight the significance of airport-based monitoring in controlling virus spread.
Clinical Enterprise, a Eurofins Scientific Company, has partnered with Ginkgo Bioworks (NYSE: DNA) to expand Operation Expanded Testing, which provides no-cost COVID-19 PCR testing to schools, community organizations, and underserved populations. This initiative, funded by the U.S. Government, supports K-12 schools, correctional facilities, and other settings to reduce transmission of the virus. Ginkgo's Concentric program facilitates testing for over 220,000 individuals weekly, aiming to promote public health equity and prevent outbreaks.
Ginkgo Bioworks (NYSE: DNA) confirmed the detection of the Omicron variant in pooled samples from air travelers arriving at Newark International Airport. This detection was part of a COVID-19 monitoring program developed in partnership with the CDC and XpresSpa Group (Nasdaq: XSPA). The program utilizes Concentric's testing infrastructure and XpresCheck's in-airport testing. Currently operational in four major airports, the initiative aims to enhance biosecurity and provide rapid public health responses. Ginkgo's Concentric has expanded its testing capabilities significantly, serving tens of millions weekly.
Ginkgo Bioworks (NYSE: DNA) announced its participation in several upcoming conferences aimed at showcasing its cell programming platform. The events include the Piper Sandler Annual Healthcare Conference on November 30, 2021, the Jefferies Alternative Protein & Related ESG Summit on December 1, 2021, and the Goldman Sachs Byte-ology Conference on December 9, 2021. More details, including webcast links and replays, will be available on their investor relations website.
On November 17, 2021, mRNA Victoria and Ginkgo Bioworks (NYSE: DNA) announced a strategic partnership aimed at enhancing vaccine development and biosecurity initiatives in Australia. Ginkgo will establish an office in Melbourne, signifying potential long-term growth in the Australian biotech sector. This collaboration leverages Ginkgo's cell programming capabilities, which have contributed to advancements in diagnostics and vaccine manufacturing, as well as other sectors like food and agriculture. Ginkgo aims to expand its operations in Australia, contributing to the local biotechnology ecosystem.
Ginkgo Bioworks, listed under ticker DNA, reported a strong third quarter for 2021 with total revenue reaching $77.6 million, up from $13.3 million in the previous year. Year-to-date revenue stands at $165.3 million, a 271% increase. Foundry revenue rose 202% to $34.7 million, while biosecurity revenue reached $42.9 million with a 48% gross margin. Despite a loss from operations of $26.7 million, cash reserves are strong at $1.7 billion. Ginkgo has exceeded its outlook for biosecurity revenue, now expecting at least $110 million for the full year.
Ginkgo Bioworks (NYSE: DNA) has launched its Cell Development Kits (CDKs) service, aimed at simplifying access for aspiring cell developers to program cells for various applications. The initial focus is on protein expression programs, providing essential tools for commercial protein development, starting at $100,000. This service is designed to reduce costs and accelerate timelines, allowing customers to prototype ideas in phases. CEO Jason Kelly emphasized the potential of engineered biology to drive innovation across multiple industries.
Synlogic (SYBX) and Ginkgo Bioworks (DNA) announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for homocystinuria (HCU). This marks the first product from their collaboration and the first developed on Ginkgo's platform to enter IND-enabling studies. Synlogic aims to file an IND application for SYNB1353 with the FDA in 2022. SYNB1353 is designed to lower plasma homocysteine by metabolizing methionine in the GI tract, providing new treatment options for patients with HCU, a disorder with limited existing therapies.
Ginkgo Bioworks (NYSE: DNA) is set to host a presentation on November 15, 2021, at 8:00 a.m. ET to discuss its third-quarter business performance for the period ending September 30, 2021. Investors can find presentation details and registration on Ginkgo's investor relations website, where a replay will also be available. Questions can be submitted beforehand via Twitter or email. Ginkgo is advancing biotechnology applications in sectors like food, agriculture, and pharmaceuticals, contributing to COVID-19 response efforts such as pooled testing and vaccine optimization.
